Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 7Breast Neoplasms 6Lung Neoplasms 5Ovarian Neoplasms 4Colorectal Neoplasms 4Pancreatic Neoplasms 3Urinary Bladder Neoplasms 2Prostatic Neoplasms 2Neoplasms 2Inflammation 2Colonic Neoplasms 2Carcinoma, Hepatocellular 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Thyroid Neoplasms 1Thrombosis 1Thromboembolism 1Stomach Neoplasms 1Solid Tumors 1Small Cell Lung Carcinoma 1Sarcoma 1Rectal Neoplasms 1Multiple Myeloma 1Melanoma 1Lymphoma 1KRAS Mutant Non-Small Cell Lung Cancer 1Immune System Diseases 1Hematologic Neoplasms 1Head and Neck Neoplasms 1Glioma 1

Interventions

palbociclib 1mirdametinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
KRAS Mutant Non-Small Cell Lung Cancer × palbociclib × Thoracic × Clear all
NCT02022982 2024-03-19

PALBOCICLIB + PD-0325901 for NSCLC & Solid Tumors

Dana-Farber Cancer Institute

Phase 1 Completed
60 enrolled
Other solid neoplasmThoracic

KRAS Mutant Non-Small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡